Intelligent Bio Solutions Q2 revenue $896,774, up 48% YoY; reader sales surge 104%

INTELLIGENT BIO SOLUTIONS INC.

2026-Q2 EPS reported -$6.27 revenue$2,008,571

Q2 total revenue $896,774, up 48% YoY; reader sales $246,519 (+104%), cartridge sales $516,754 (+33%).
First-half FY2026 revenue $2.01M (+36% YoY); gross margin improved to 49% from 39%.
Closed $10M private placement (net $9.4M received Jan 2, 2026) for working capital and FDA 510(k) submission.
Initiated additional clinical studies for FDA 510(k); plans for U.S. market entry.
Strategic alliance with Vlepis Pty Ltd for consumer health monitoring; major industrial service contract.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.